← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Fox Chase Chemical Diversity Center, Inc
Doylestown, PA
$49,901,426
Total funding
38
Grants
Funding over time
peak $5M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,901,426 · 38
By mechanism
R44$21,276,257 · 8
R42$12,002,381 · 5
U01$7,375,647 · 1
R41$6,164,387 · 16
R43$2,776,254 · 7
N43$306,500 · 1
Investigators at Fox Chase Chemical Diversity Center, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,438,738
U01 · FY2025 · AG
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,412,771
U01 · FY2021 · AG
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,386,046
U01 · FY2022 · AG
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,365,008
U01 · FY2023 · AG
Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders$1,363,709
U01 · FY2024 · AG
Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses$1,197,020
R44 · FY2016 · AI
Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses$1,110,810
R44 · FY2015 · AI
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$1,050,000
R44 · FY2023 · AI
Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis$1,050,000
R42 · FY2022 · AI
Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum$1,039,551
R42 · FY2024 · AI
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1,017,000
R42 · FY2021 · AI
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1,015,449
R42 · FY2022 · AI
Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses$1,012,857
R42 · FY2023 · AI
DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM$1,002,225
R44 · FY2017 · AI
DEVELOPMENT OF TOPICAL ANTIVIRAL AGENTS FOR TREATING MOLLUSCUM CONTAGIOSUM$1,002,030
R44 · FY2016 · AI
Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV_AIDS$1,001,024
R42 · FY2016 · GM
Riluzole Prodrugs for Melanoma and ALS$1,000,000
R44 · FY2018 · CA
Riluzole Prodrugs for Melanoma and ALS$1,000,000
R44 · FY2019 · CA
Development of Small Antimicrobial Peptide Mimics as Drug-Resistant and Susceptib$1,000,000
R44 · FY2013 · AI
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle$1,000,000
R44 · FY2025 · AI